

RESEARCH ARTICLE

Open Access



Immunoglobulin G N-glycan, inflammation and type 2 diabetes in East Asian and European populations: a Mendelian randomization study

Biyang Wang¹, Di Liu^{1,2}, Manshu Song³, Wei Wang³, Bo Guo^{4*} and Youxin Wang^{1*} 

Abstract

Background: Immunoglobulin G (IgG) N-glycans have been shown to be associated with the risk of type 2 diabetes (T2D) and its risk factors. However, whether these associations reflect causal effects remain unclear. Furthermore, the associations of IgG N-glycans and inflammation are not fully understood.

Methods: We examined the causal associations of IgG N-glycans with inflammation (C-reactive protein (CRP) and fibrinogen) and T2D using two-sample Mendelian randomization (MR) analysis in East Asian and European populations. Genetic variants from IgG N-glycan quantitative trait loci (QTL) data were used as instrumental variables. Two-sample MR was conducted for IgG N-glycans with inflammation (75,391 and 18,348 participants of CRP and fibrinogen in the East Asian population, 204,402 participants of CRP in the European population) and T2D risk (77,418 cases and 356,122 controls of East Asian ancestry, 81,412 cases and 370,832 controls of European ancestry).

Results: After correcting for multiple testing, in the East Asian population, genetically determined IgG N-glycans were associated with a higher risk of T2D, the odds ratios (ORs) were 1.009 for T2D per 1- standard deviation (SD) higher GP5, 95% CI = 1.003–1.015; $P=0.0019$; and 1.013 for T2D per 1-SD higher GP13, 95% CI = 1.006–1.021; $P=0.0005$. In the European population, genetically determined decreased GP9 was associated with T2D (OR = 0.899 per 1-SD lower GP9, 95% CI: 0.845–0.957). In addition, there was suggestive evidence that genetically determined IgG N-glycans were associated with CRP in both East Asian and European populations after correcting for multiple testing, but no associations were found between IgG N-glycans and fibrinogen. There was limited evidence of heterogeneity and pleiotropy bias.

Conclusions: Our results provided novel genetic evidence that IgG N-glycans are causally associated with T2D.

Keywords: Type 2 diabetes, Immunoglobulin G, N-glycans, Inflammation, Mendelian randomization

Background

Type 2 diabetes (T2D) is a chronic disease characterized by relative insulin deficiency and peripheral insulin resistance with a high societal burden (Chatterjee et al. 2017; Khan et al. 2020; Liang et al. 2020). It is estimated that over 642 million T2D patients by 2030 (Chen et al. 2011). Although many environmental and genetic risk factors have been identified, the underlying mechanisms of different polygenic multifactorial chronic complex disorders like T2D remain uncertain (Tremblay and Hamet 2019).

*Correspondence: drguobo@163.com; wangy@ccmu.edu.cn

¹ Beijing Municipal Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, 10 Xitoutiao, Beijing 100069, China

⁴ Department of Hematology, The Second Medical Centre and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing 100853, China

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Glycosylation is the most frequent posttranslational modification, constituting the composition of proteins, modulating their function and participating in many key biological processes, including protein folding, molecular trafficking and clearance, cell adhesion and immune regulation (Krištić and Lauc 2017; Kronimus et al. 2019). Immunoglobulin G (IgG) represents a highly abundant protein and constitutes an important part of humoral immune response (Nimmerjahn and Ravetch 2008). N-glycans are linked to conserved asparagine-297 in the Fc part of IgG, and switch its function between pro- and anti-inflammatory (Kronimus et al. 2019; Yamaguchi and Barb 2020). C-reactive protein (CRP) and fibrinogen can be considered as well-proven clinical markers of systemic inflammation, which are synthesized by hepatocytes against inflammation (Dalmon et al. 1993; Pepys and Hirschfield 2003). Previous studies suggest that alterations of IgG N-glycans can mediate inflammatory responses, and thus are associated with T2D risk (Novokmet et al. 2014; Plomp et al. 2017). A number of observational studies have also demonstrated that aberrant IgG N-glycans affect the pathogenesis of several chronic inflammatory diseases (Ercan et al. 2010; Jin et al. 2013; Trbojević Akmačić et al. 2015; Liu et al. 2018b; Pavić et al. 2018).

Limited data available from observational studies suggested that IgG N-glycan changes have been linked to clinical risk factors of T2D, such as age (Krištić et al. 2014), BMI (Nikolac Perkovic et al. 2014; Greto et al. 2021), and dyslipidemia (Liu et al. 2018a). Furthermore, IgG N-glycans have been identified to be correlated with T2D in several case–control and prospective studies (Lemmers et al. 2017; Dotz et al. 2018; Li et al. 2019; Wittenbecher et al. 2020). Although there is a growing consensus that the role of IgG N-glycosylation is involved in the development of T2D, it remains unclear whether the associations of IgG N-glycans and T2D are causal or a proxy for unmeasured confounding factors, and the population-scale evidence for the effects of IgG N-glycans on

inflammation is scarce. Understanding the specific associations of IgG N-glycosylation and T2D would help to reveal the underlying inflammatory pathophysiological processes and drug target of T2D. Consequently, further study is needed to investigate the causality between the alterations of IgG N-glycosylation and T2D.


Mendelian randomization (MR) studies, which use genetic variants as instrumental variables for exposure, can further support causality due to their randomly allocated nature and circumvent confounding and reverse causation (Emdin et al. 2017). None of previous study on causality of IgG N-glycans and T2D used the MR design so far. In this study, given the ethnic-specific differences of IgG N-glycans (Gebrehiwot et al. 2018; Štambuk et al. 2020), we aimed to estimate the effects of genetically predicted IgG N-glycans on T2D risk using two-sample MR in East Asian and European populations, respectively. Second, we aimed to examine the potential associations of genetically predicted IgG N-glycans with inflammation (including CRP and fibrinogen).

Methods

Study design and data source

We used two-sample MR to examine the associations of IgG N-glycans with T2D risk, and IgG N-glycans with inflammation (including CRP and fibrinogen) in East Asian and European populations (Fig. 1). The two-sample MR design is under the assumption that the genetic variants are associated with exposure, but not with confounders. Besides, the genetic variants affect risk of outcome only through exposure and not through any alternative pathways.

In the East Asian population, information on genetic variants associated with IgG N-glycan was collected from IgG N-glycan quantitative trait loci (IgG N-glycan-QTL) summarized data (Liu et al. 2018a, 2022). This genome-wide association study (GWAS) involved 536 individuals from a cross-sectional study, and 7,108,659 single nucleotide polymorphisms (SNPs) of each IgG N-glycan



(24 glycan peaks) (excluding SNP with call rate < 99%, minor allele frequency < 0.01 and imputation quality ratio < 0.7) (Liu et al. 2022). The IgG N-glycans were quantified using ultra-performance liquid chromatography (UPLC) and 24 glycan peaks (GPs) were separated from IgG N-glycans. The detail structures of each glycan peak are described in Additional file 2: Table S1. Genotyping was performed on Illumina Omni Zhonghua chips (Illumina, San Diego, CA, USA) in this GWAS (Liu et al. 2020). Summary statistics data on associations of genetic variants with CRP and fibrinogen were accessed through a published large-scale GWAS by Biobank Japan, which included 75,391 and 18,348 participants respectively (Kanai et al. 2018). Data on association of genetic variants with T2D were obtained from a published GWAS meta-analysis by of 77,418 cases and 356,122 controls (Spracklen et al. 2020). In the European population, summary statistics data on associations of genetic variants with IgG N-glycan were accessed through a recently published GWAS (Klarić et al. 2020). The IgG N-glycans were also detected by UPLC and separated to 24 GPs. We also obtained association summary statistics with CRP and T2D from respective GWAS studies (Ligthart et al. 2018; Mahajan et al. 2018). GWASs included in the current study are described in detail in Table 1.

Genetic instruments for IgG N-glycans

Independent SNPs (low linkage disequilibrium (LD), $R^2 < 0.001$) associated with IgG N-glycans were identified as instrumental variables (IVs). The selected SNPs were independent, namely, not in linkage disequilibrium ($R^2 < 0.001$). Independently associated SNPs ($P < 5 \times 10^{-8}$) with IgG N-glycans were selected in European ancestry. Because few genetic variants were available, referring previous studies (Savage et al. 2018; Dong et al. 2021), a relatively relaxed threshold ($P < 1 \times 10^{-5}$) was used to select SNPs in the East Asian population. Then, the F -statistic (β^2/se^2) was applied to evaluate the strength

for each SNP, and SNPs with less statistical power (F -statistics < 10) were removed to avoid weak IV bias.

Statistical analysis

First, two-sample MR analyses were performed to disentangle the potential associations of IgG N-glycans and T2D. For MR analyses, conventional inverse variance weighting (IVW) (Burgess et al. 2013) and three sensitivity analyses including MR-Egger regression (Bowden et al. 2015), weighted median (WM) (Bowden et al. 2016) and penalized weighted median (PWM) were utilized to compute robust causal estimates on outcome of exposures (Liu et al. 2021). When only 2 SNPs were available, the IVW method was used. Sensitivity analysis was used when more than 2 SNPs are available. Heterogeneity of individual genetic variants effect was estimated by Cochran's Q test (Bowden et al. 2018). Multiplicative random effects IVW models are used when heterogeneity exist. MR-Egger regression analysis can also assess the directional pleiotropy based on its intercepts (Burgess and Thompson 2017). Only 2 SNPs were available, thus we searched each IV in the PhenoScanner v2 to determine potential pleiotropy (Kamat et al. 2019) (Additional file 1: Table S2). In addition, we also provided scatter plots and leave-one-out plots for further interpretation. Leave-one-out analyses were performed to test the influence of outlying or genetic variants pleiotropy (Burgess and Thompson 2017). All results are presented as odds ratios (OR) with their 95% confidence interval (CI) of outcomes per genetically predicted increase in each exposure factor. To take into account multiple testing, Bonferroni corrected P value threshold for 24/17 exposures ($P < 0.002/0.003$) was used to indicate statistical significance. $P < 0.05$ but above the Bonferroni corrected significance threshold was considered as suggestive evidence for a potential association. All analyses were performed with R (version 4.0.2) with the "TwoSampleMR" and "MendelianRandomization" packages.

Table 1 Characteristics of the GWAS used in this study

Phenotype	Sample size	Ancestry	Citation	PMID
IgG N-glycans	536	East Asian	Liu et al. (2022)	35545292
CRP	75,391	East Asian	Kanai et al. (2018) http://jenger.riken.jp/en/result/	29403010
Fibrinogen	18,348	East Asian	Kanai et al. (2018) http://jenger.riken.jp/en/result/	29403010
T2D	77,418 cases and 356,122 controls	East Asian	Spracklen et al. (2020)	32499647
IgG N-glycans	8090	European	Klarić et al. (2020)	32128391
CRP	204,402	European	Ligthart et al. (2018)	30388399
T2D	81,412 cases and 370,832 controls	European	Mahajan et al. (2018)	29632382

GWAS genome-wide association study, IgG Immunoglobulin G, CRP C-reactive protein, T2D type 2 diabetes

Results

Associations of IgG N-glycans with T2D risk


The summary genetic association data of each GP are reported in the Additional file 1: Tables S3 and S4. The *F*-statistics for all SNPs are >10 (Additional file 1: Tables S3 and S4), suggesting that the selected SNPs have sufficiently strong effects as IVs and unlikely have weak instrument bias. In the East Asian population, MR results showed positive effects of genetically determined GP5 and GP13 on T2D after multiple testing (IVW OR, 1.009 for T2D per 1-SD higher GP5, 95% CI=1.003–1.015; *P*=0.0019; 1.013 for T2D per 1-SD higher GP13, 95% CI=1.006–1.021; *P*=0.0005; Figs. 2, 3 and Table 2). The results of genetically determined GP13 with T2D are remain robust in three sensitivity analysis (WM OR_{GP13}=1.012, 95% CI=1.001–1.023, PWM OR_{GP13}=1.013, 95% CI=1.006–1.021, MR-Egger OR_{GP13}=1.003, 95% CI=1.000–1.006). However, no significant effects of genetically predicted GP5 and GP22 on T2D were observed in WM and PWM estimates (Table 2). The MR analyses showed that there was no pleiotropy bias and heterogeneity in 21 genetically instrumented IgG N-glycans (all *P*s>0.05), except GP5, GP7, and GP17 (Table 2). Additionally, the leave-one-out analysis showed no marked difference in causal estimations of GP5 and GP13 on T2D in the conditions that anyone SNP was excluded, suggesting that the inverse

associations were not substantially driven by any individual SNP (Fig. 3).

In the European population, genetically determined GP9 is associated with a higher risk of T2D after multiple testing (IVW OR, 0.899 for T2D per 1-SD lower GP9, 95% CI=0.845–0.957; *P*=0.0008; Figs. 2, 4 and Table 3). The results of genetically determined GP9 with T2D are remain robust in WM and PWM sensitivity analysis (WM OR_{GP9}=0.924, 95% CI=0.866–0.985, PWM OR_{GP9}=0.924, 95% CI=0.868–0.984). And the results of IVW are reliable from the results of directional pleiotropy of GP9 on T2D (Table 3). However, no significant effects of genetically predicted GP5 and GP13 on T2D were observed in the European population. The MR-Egger method detected no evidence of directional pleiotropy among each GP for T2D (all *P*s>0.05, Table 3). IVW results using multiplicative random-effects models are presented when heterogeneity exist. The results of leave-one-out sensitivity analysis support that no single SNP drove the overall association between GP9 and T2D (Fig. 4).

Associations of IgG N-glycans with inflammation

There was a suggestive association between genetically predicted higher GP14 and CRP in IVW models after multiple testing (OR, 1.009 for CRP per 1-SD higher in GP14, 95% CI=1.001–1.032, *P*=0.0350; Additional file 2: Table S5). In addition, as shown in Additional file 2:






Table S6, genetically predicted IgG N-glycans were not associated with fibrinogen (for GP1-GP24, all $P_s > 0.05$). The MR-Egger and Cochran’s Q method detected few evidences of directional pleiotropy and heterogeneity among each GP for CRP and fibrinogen (Additional file 2: Table S5 and Table S6), and IVW multiplicative random-effects models were used when heterogeneity existed. In

the European population, there were suggestive associations between genetically determined IgG N-glycans on CRP after multiple testing (IVW OR, 1.031 for CRP per 1-SD higher GP12, 95% CI=1.003–1.060, $P=0.0278$; 1.032 for CRP per 1-SD higher GP13, 95% CI=1.003–1.061, $P=0.0278$; 1.066 for CRP per 1-SD higher GP22, 95% CI=1.005–1.131, $P=0.0323$; Additional file 2:

Table 2 MR estimates of IgG glycans with T2D in the East Asian population

Exposure	SNPs	IVW		WM		PWM		MR-Egger		P _{pleiotropy}	P _{heterogeneity}
		OR (95%CI)	P								
GP1	124	1.003(0.999–1.007)	0.1550	1.000(0.994–1.006)	0.9993	1.000(0.994–1.005)	0.9704	0.998(0.990–1.006)	0.5792	0.1423	0.1989
GP2	32	1.008(1.000–1.017)	0.0627	1.013(1.001–1.026)	0.0401	1.013(1.001–1.026)	0.0300	1.009(0.993–1.025)	0.2740	0.9198	0.6452
GP3	32	1.006(0.997–1.016)	0.1791	1.007(0.995–1.019)	0.2574	1.009(0.997–1.021)	0.1446	0.996(0.979–1.014)	0.6859	0.2018	0.1330
GP4	24	1.001(0.988–1.013)	0.9283	0.998(0.982–1.014)	0.7695	0.997(0.981–1.013)	0.7380	1.005(0.981–1.029)	0.7126	0.7046	0.1766
GP5	66	1.009(1.003–1.015)	0.0019	1.005(0.996–1.013)	0.3010	1.004(0.997–1.012)	0.2684	1.000(0.989–1.010)	0.9593	0.0446	0.2855
GP6	19	1.006(0.992–1.020)	0.4101	1.004(0.985–1.022)	0.6993	1.003(0.985–1.022)	0.7091	1.003(0.979–1.028)	0.7973	0.8061	0.2320
GP7	24	0.988(0.970–1.005)	0.1680	0.995(0.981–1.009)	0.4491	0.995(0.981–1.009)	0.5037	0.984(0.948–1.021)	0.3885	0.8055	<0.0001
GP8	13	0.990(0.972–1.008)	0.2744	0.987(0.967–1.008)	0.2174	0.981(0.960–1.001)	0.0663	0.976(0.931–1.023)	0.3313	0.5336	0.0642
GP9	13	0.998(0.984–1.013)	0.8406	1.003(0.983–1.022)	0.7996	1.003(0.984–1.022)	0.7905	0.988(0.952–1.025)	0.5315	0.5477	0.2248
GP10	23	0.996(0.986–1.005)	0.3867	0.997(0.981–1.013)	0.6886	0.997(0.981–1.012)	0.6393	1.008(0.986–1.030)	0.4867	0.2328	0.5558
GP11	13	0.993(0.979–1.007)	0.3528	1.000(0.981–1.020)	0.9860	1.000(0.981–1.020)	0.9789	0.996(0.965–1.028)	0.7961	0.8698	0.5027
GP12	39	1.000(0.992–1.008)	0.9564	1.001(0.990–1.013)	0.8344	1.001(0.990–1.012)	0.8446	1.007(0.993–1.022)	0.3441	0.2724	0.3584
GP13	41	1.013(1.006–1.021)	0.0005	1.012(1.001–1.023)	0.0377	1.012(1.001–1.023)	0.0371	1.017(1.003–1.031)	0.0227	0.5362	0.7358
GP14	16	1.001(0.986–1.016)	0.8952	1.002(0.982–1.022)	0.8563	1.002(0.982–1.022)	0.8580	0.998(0.964–1.034)	0.9310	0.8748	0.1536
GP15	14	0.995(0.980–1.011)	0.5562	1.006(0.986–1.025)	0.5835	1.007(0.987–1.026)	0.5174	0.977(0.939–1.015)	0.2575	0.3193	0.4690
GP16	21	1.001(0.991–1.012)	0.7972	1.000(0.985–1.014)	0.9610	1.000(0.985–1.015)	0.9615	1.001(0.974–1.029)	0.9269	0.9977	0.0111
GP17	49	1.003(0.995–1.011)	0.5221	1.001(0.991–1.011)	0.8529	1.001(0.991–1.011)	0.8459	1.011(0.995–1.026)	0.1783	0.2327	0.1484
GP18	12	1.003(0.985–1.022)	0.7327	1.015(0.992–1.038)	0.2019	1.017(0.995–1.040)	0.1300	0.986(0.939–1.035)	0.5792	0.4608	0.0671
GP19	22	1.001(0.989–1.012)	0.9151	1.004(0.990–1.018)	0.5898	1.004(0.990–1.018)	0.5978	1.011(0.988–1.035)	0.3525	0.3129	0.5478
GP20	60	0.999(0.993–1.005)	0.7385	0.996(0.988–1.004)	0.3332	0.996(0.987–1.004)	0.3304	1.004(0.991–1.018)	0.5040	0.3621	0.3163
GP21	27	1.003(0.993–1.012)	0.5990	0.998(0.985–1.012)	0.8107	0.998(0.985–1.012)	0.8143	1.001(0.981–1.021)	0.9496	0.8277	0.1124
GP22	184	1.003(1.000–1.006)	0.0464	1.003(0.999–1.008)	0.1216	1.003(0.999–1.008)	0.1326	1.007(1.000–1.015)	0.0441	0.1875	0.3638
GP23	16	0.994(0.982–1.006)	0.3202	0.999(0.982–1.016)	0.9474	1.001(0.985–1.017)	0.9256	0.992(0.963–1.021)	0.5822	0.8687	0.4984
GP24	17	0.999(0.987–1.011)	0.8538	1.001(0.985–1.018)	0.8899	1.001(0.985–1.018)	0.8887	1.012(0.978–1.047)	0.5068	0.4414	0.4984

MR Mendelian randomization, T2D type 2 diabetes, IVW inverse variance weighting, WM weighted median, PWM penalized weighted median, OR odds ratio, CI confidence interval, SMP single-nucleotide polymorphism, GP glycan peak, P_{heterogeneity} is the P-value of Cochran's Q value in heterogeneity test by performing Inverse variance weighted method; P_{pleiotropy} is the P-value of MR-Egger intercept




Table S7). No directional pleiotropy was detected in MR-Egger method (Additional file 2: Table S7).

Discussion

In the present study, we are the first to describe the associations of genetically predicted IgG N-glycans with T2D, and assess the potential effects of IgG N-glycans on inflammation (including CRP and fibrinogen) using two-sample MR study in East Asian and European populations, respectively. The MR results showed that increased genetically predicted IgG N-glycans of GP5 and GP13 were associated with a higher risk of T2D in the East Asian population, and genetically predicted decreased GP9 was associated with a higher risk of T2D in the European population. In addition, there were suggestive associations of genetically predicted IgG N-glycans on CRP both in East Asian and European populations.

Several previous observational studies have investigated that the associations between IgG N-glycans and risk of T2D (Lemmers et al. 2017; Li et al. 2019), whereas those results might be limited because of reverse causality or unmeasured confounding factors. Our analyses help to clarify the causal relationship and infer a direction of effect, which is not possible in observational studies due to potential reverse causation. In addition, our findings were consistent with previous studies that have

also reported that N-glycosylation was associated with increased risk of T2D (Keser et al. 2017; Dotz et al. 2018; Rudman et al. 2019) and its complications (Itoh et al. 2007; Testa et al. 2015; Singh et al. 2020). A study involving three populations also confirmed that the increased complexity of plasma N-glycans including branching, galactosylation and sialylation are associated with higher risk of T2D (Keser et al. 2017). A case-cohort study presented that plasma N-glycome can identify high risk individuals before the onset of T2D, with the AUC value of the model consisting of plasma N-glycans to distinguish T2D from control as 0.83 (Wittenbecher et al. 2020).

Although the results of IgG N-glycans and risk of T2D were statistically significant, these findings were inconsistent in East Asian and European populations. The differences of associations between IgG N-glycans and T2D can be explained by ethnic differences of IgG N-glycans, as reported in previous studies (Gebrehiwot et al. 2018; Štambuk et al. 2020). IgG Fc segment is connected to complex-type biantennary N-glycan structures, which can control the binding affinity of IgG to activate or inhibit IgG Fcγ receptors, thereby affecting the effector function of IgG (Maverakis et al. 2015). The pro- and anti-inflammatory effects of IgG are modulated by modifications of N-glycan including galactose, fucose, sialic acid, and bisecting GlcNAc (Maverakis et al. 2015). In the

Table 3 MR estimates of IgG glycans with T2D in the European population

Exposure	SNPs	IVW		WM		PWM		MR-Egger		$P_{\text{pleiotropy}}$	$P_{\text{heterogeneity}}$
		OR (95%CI)	P								
GP2	7	0.999(0.965–1.034)	0.9497	1.009(0.971–1.048)	0.6515	1.010(0.969–1.052)	0.6251	1.042(0.947–1.146)	0.4365	0.3931	0.2717
GP4	2	0.985(0.846–1.148)	0.8530	–	–	–	–	–	–	–	0.0881
GP6	4	0.999(0.910–1.099)	0.9992	0.966(0.896–1.042)	0.3766	0.956(0.884–1.034)	0.2642	1.049(0.459–2.856)	0.8005	0.7990	0.0361
GP7	5	0.979(0.933–1.028)	0.4033	0.993(0.941–1.049)	0.8131	0.994(0.941–1.049)	0.8215	1.055(0.953–1.168)	0.2080	0.2080	0.3010
GP8	2	1.041(0.923–1.174)	0.5147	–	–	–	–	–	–	–	0.1993
GP9	4	0.899(0.845–0.957)	0.0008	0.924(0.866–0.985)	0.0198	0.924(0.868–0.984)	0.0198	1.046(0.853–1.284)	0.7046	0.2723	0.2293
GP10	5	0.997(0.929–1.068)	0.9256	0.963(0.910–1.018)	0.1831	0.951(0.902–1.002)	0.0617	1.033(0.820–1.301)	0.8003	0.7669	0.0137
GP11	3	1.003(0.869–1.156)	0.9708	0.938(0.867–1.014)	0.1077	0.937(0.869–1.012)	0.0957	0.925(0.476–1.799)	0.8455	0.8455	0.0035
GP12	3	1.008(0.958–1.060)	0.7625	1.009(0.955–1.067)	0.7363	1.009(0.955–1.067)	0.7361	1.046(0.903–1.213)	0.6546	0.6890	0.8679
GP13	3	1.008(0.958–1.060)	0.7625	1.009(0.956–1.066)	0.7324	1.009(0.954–1.067)	0.7405	1.046(0.903–1.212)	0.6546	0.6890	0.8679
GP14	4	0.992(0.887–1.108)	0.8824	0.928(0.905–1.043)	0.4290	0.928(0.853–1.009)	0.0838	0.936(0.538–1.627)	0.8365	0.8524	0.0034
GP15	7	0.981(0.907–1.061)	0.6331	0.966(0.900–1.035)	0.3258	0.951(0.889–1.016)	0.1361	0.939(0.551–1.603)	0.8283	0.8791	0.0053
GP16	5	1.017(0.981–1.054)	0.3652	1.032(1.003–1.062)	0.0304	1.033(1.004–1.063)	0.0248	1.099(1.028–1.175)	0.0691	0.0910	0.0655
GP18	3	1.057(0.984–1.136)	0.1281	1.064(1.000–1.132)	0.0499	1.064(1.000–1.132)	0.0490	1.216(0.684–2.162)	0.6246	0.7125	0.1389
GP20	2	0.925(0.561–1.524)	0.7289	–	–	–	–	–	–	–	< 0.0001
GP22	2	1.014(0.931–1.104)	0.7502	–	–	–	–	–	–	–	0.4754
GP23	3	1.022(0.895–1.167)	0.7487	1.058(0.976–1.147)	0.1705	1.093(1.018–1.173)	0.0135	0.026(0.003–2.425)	0.1793	0.1782	0.0016

MR Mendelian randomization, IVW inverse variance weighting, WM weighted median, PWM penalized weighted median, OR odds ratio, CI confidence interval, SNP single-nucleotide polymorphism, GP glycan peak, $P_{\text{heterogeneity}}$ is the P-value of Cochran's Q value in heterogeneity test by performing inverse variance weighted method; $P_{\text{pleiotropy}}$ is the P-value of MR-Egger intercept

East Asian population, our analyses showed that genetically determined GP5 and GP13 were increasingly associated with T2D. Specifically the results demonstrated that the pathophysiology of T2D were predominantly explained with increased of GP5 (abundance of a high-mannose N-glycan structure), as well as GP13 containing bisecting GlcNAc. In general, IgG carrying bisecting GlcNAc is associated with increased FcγRIII affinities, thus enhancing antibody-dependent cellular cytotoxicity (ADCC) activity (Zou et al. 2011). In consistent with our results, evidence from several studies showed that higher bisecting GlcNAc was elevated in response to inflammatory diseases (Vučković et al. 2015; Greto et al. 2021). However, effect of mannose N-glycan structure has not yet been fully clarified. Higher mannose GP5 was associated with systemic lupus erythematosus (Vučković et al. 2015), while previous studies showed that lower GP5 was associated with ischemic stroke (Liu et al. 2018b) and parkinson's disease (Russell et al. 2017). In the European population, genetically determined decreased GP9 was associated with T2D, suggesting that decreased galactosylation may increase the risk of T2D, which is consistent with previous studies (Nikolac Perkovic et al. 2014; Liu et al. 2018b). IgG N-glycans with decreased galactosylation mediate pro-inflammatory activity by recognizing mannose binding lectin (MBL) and activating subsequent complement (Matsumoto et al. 2000). Decreased galactosylation also enhance FcγRIII affinity, thus enhancing ADCC activity (Ackerman et al. 2013), and galactose deficiency also affects sialylation to regulate immune response.

The MR results provided only suggestive evidence that the effects of genetically determined IgG N-glycans on CRP, thus mediation analyses were technically unnecessary to perform. It is well know that T2D is a multifactorial disorder and a multi-layered process, besides regulating the immune response pathway, N-glycans is also involved in the etiology of insulin resistance (Pradhan et al. 2001). And inhibitory IgG receptor FcγRIIB plays an important role in activating obesity induced insulin resistance in microvascular endothelium (Tanigaki et al. 2018). Previous studies indicated that the faintly aberrant IgG glycosylation might play a cascading role in the pathogenesis of inflammatory disease (Liu et al. 2018b). A possible explanation for the inconsistent results in observational and our MR studies is that the sample sizes of IgG N-glycan GWAS from both European and Asian ethnic were too small to identify differences.

Although our study is a first MR analysis to explore this causality in East Asian and European populations so far, there are several limitations. Firstly, due to the relatively small sample sizes of East Asian ancestry, we did not filter out enough instrumental variables at $P < 5 \times 10^{-8}$.

Therefore, we used SNPs meeting a more relaxed threshold at $P < 1 \times 10^{-5}$, which has been used in previous MR studies (Dong et al. 2021). The *F*-statistics of all selected SNPs are > 10 , suggesting that all SNPs have sufficiently strong effects as IVs. Secondly, we only assessed CRP and fibrinogen as inflammation, but the levels of these inflammatory markers may not reflect the degree of inflammation in individuals. Thirdly, the effect sizes identified in our study are relatively small, however, the primary purpose of MR analysis is estimating the causal effects of exposures on outcome. Finally, since most SNPs related with IgG N-glycans could not be found corresponding SNPs in outcome of fibrinogen GWAS, IgG N-glycans and fibrinogen were not analyzed in the European population. This may also suggest that there is no causal relationship between genetically determined IgG N-glycan and fibrinogen.

Conclusions

In conclusion, we demonstrated that genetically predicted IgG N-glycans were associated with T2D both in East Asian and European populations. In addition, there was suggestive genetic evidence for potential associations of genetically predicted IgG N-glycans and CRP. A more large-scale IgG N-glycan-QTL and further investigation are likely needed to validate our findings, and to clarify the mechanistic pathways of T2D.

Abbreviations

T2D: Type 2 diabetes; IgG: Immunoglobulin G; MR: Mendelian randomization; CRP: C-reactive protein; IgG N-glycan-QTL: IgG N-glycan quantitative trait loci; GWAS: Genome-wide association study; SNP: Single nucleotide polymorphism; GP: Glycan peak; UPLC: Ultra-performance liquid chromatography; LD: Linkage disequilibrium; IV: Instrumental variable; IVW: Inverse variance weighting; WM: Weighted median; PWM: Penalized weighted median; CI: Confidence interval; ADCC: Antibody-dependent cellular cytotoxicity; MBL: Mannose binding lectin.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s10020-022-00543-z>.

Additional file 1: Table S2. Results of each genetic variants (less than 3 SNPs) in the PhenoScanner v2. **Table S3.** Genetic variants used to instrument GPs in East Asian population. **Table S4.** Genetic variants used to instrument GPs in European population.

Additional file 2: Table S1. Description of glycans structures of 24 glycan peaks. **Table S6.** Mendelian randomization (MR) estimates of IgG glycans with fibrinogen from different MR methods in East Asian population.

Table S7. Mendelian randomization (MR) estimates of IgG glycans with CRP from different MR methods in European population.

Acknowledgements

We thank all the research participants and data on CRP and fibrinogen associated single nucleotide polymorphisms were accessed through BioBank Japan. Data on other exposure and outcome associated single nucleotide polymorphisms have been derived from published articles (Ligthart et al. 2018; Mahajan et al. 2018; Klarić et al. 2020; Spracklen et al. 2020).

Author contributions

YW and BG conceived and designed the study. BW and DL contributed to the data analysis. BW wrote the original draft. MS, WW, BG, YW reviewed and edited manuscript. All authors have read and approved the final manuscript.

Funding

This work was supported by the National Nature Science Foundation of China [NSFC 81872682].

Availability of data and materials

The datasets supporting the conclusions of this article are available in the repositories listed in Table 1 and additional files.

Declarations**Ethics approval and consent to participate**

This analysis of publicly available data does not require ethical approval.

Consent for publication

Not applicable.

Competing interests

The authors declare no financial or other conflicts of interest.

Author details

¹Beijing Municipal Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, 10 Xitoutiao, Beijing 100069, China. ²Centre for Biomedical Information Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China. ³School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia. ⁴Department of Hematology, The Second Medical Centre and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing 100853, China.

Received: 14 April 2022 Accepted: 7 September 2022

Published online: 14 September 2022

References

- Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. *J Clin Invest*. 2013;123(5):2183–92. <https://doi.org/10.1172/jci65708>.
- Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512–25. <https://doi.org/10.1093/ije/dyv080>.
- Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40(4):304–14. <https://doi.org/10.1002/gepi.21965>.
- Bowden J, Hemani G, Davey SG. Invited commentary: detecting individual and global horizontal pleiotropy in Mendelian randomization—a job for the humble heterogeneity statistic? *Am J Epidemiol*. 2018;187(12):2681–5. <https://doi.org/10.1093/aje/kwy185>.
- Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol*. 2017;32(5):377–89. <https://doi.org/10.1007/s10654-017-0255-x>.
- Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. 2013;37(7):658–65. <https://doi.org/10.1002/gepi.21758>.
- Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet*. 2017;389(10085):2239–51. [https://doi.org/10.1016/s0140-6736\(17\)30058-2](https://doi.org/10.1016/s0140-6736(17)30058-2).
- Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. *Nat Rev Endocrinol*. 2011;8(4):228–36. <https://doi.org/10.1038/nrendo.2011.183>.
- Dalmon J, Laurent M, Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. *Mol Cell Biol*. 1993;13(2):1183–93. <https://doi.org/10.1128/mcb.13.2.1183-1193.1993>.
- Dong SS, Zhang K, Guo Y, Ding JM, Rong Y, Feng JC, et al. Phenome-wide investigation of the causal associations between childhood BMI and adult trait outcomes: a two-sample Mendelian randomization study. *Genome Med*. 2021;13(1):48. <https://doi.org/10.1186/s13073-021-00865-3>.
- Dotz V, Lemmers RFH, Reiding KR, Hipgrave Ederveen AL, Lieverse AG, Mulder MT, et al. Plasma protein N-glycan signatures of type 2 diabetes. *Biochim Biophys Acta Gen Subj*. 2018;1862(12):2613–22. <https://doi.org/10.1016/j.bbagen.2018.08.005>.
- Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. *JAMA*. 2017;318(19):1925–6. <https://doi.org/10.1001/jama.2017.17219>.
- Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. *Arthritis Rheum*. 2010;62(8):2239–48. <https://doi.org/10.1002/art.27533>.
- Gebrehiwot AG, Melka DS, Kassaye YM, Rehan IF, Rangappa S, Hinou H, et al. Healthy human serum N-glycan profiling reveals the influence of ethnic variation on the identified cancer-relevant glycan biomarkers. *PLoS ONE*. 2018;13(12):e0209515. <https://doi.org/10.1371/journal.pone.0209515>.
- Greto VL, Cvetko A, Štambuk T, Dempster NJ, Kifer D, Deriš H, et al. Extensive weight loss reduces glycan age by altering IgG N-glycosylation. *Int J Obes (Lond)*. 2021;45(7):1521–31. <https://doi.org/10.1038/s41366-021-00816-3>.
- Itoh N, Sakaue S, Nakagawa H, Kuroguchi M, Ohira H, Deguchi K, et al. Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes. *Am J Physiol Endocrinol Metab*. 2007;293(4):E1069–1077. <https://doi.org/10.1152/ajpendo.00182.2007>.
- Jin R, Liu L, Zhang S, Nanda A, Li G. Role of inflammation and its mediators in acute ischemic stroke. *J Cardiovasc Transl Res*. 2013;6(5):834–51. <https://doi.org/10.1007/s12265-013-9508-6>.
- Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics*. 2019;35(22):4851–3. <https://doi.org/10.1093/bioinformatics/btz469>.
- Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat Genet*. 2018;50(3):390–400. <https://doi.org/10.1038/s41588-018-0047-6>.
- Keser T, Gornik I, Vučković F, Selak N, Pavić T, Lukić E, et al. Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes. *Diabetologia*. 2017;60(12):2352–60. <https://doi.org/10.1007/s00125-017-4426-9>.
- Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KI. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. *J Epidemiol Glob Health*. 2020;10(1):107–11. <https://doi.org/10.2991/jegh.k.191028.001>.
- Klarić L, Tsepilov YA, Stanton CM, Mangino M, Sikka TT, Esko T, et al. Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. *Sci Adv*. 2020;6(8):eaax0301. <https://doi.org/10.1126/sciadv.aax0301>.
- Krištić J, Lauc G. Ubiquitous importance of protein glycosylation. *Methods Mol Biol*. 2017;1503:1–12. https://doi.org/10.1007/978-1-4939-6493-2_1.
- Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. *J Gerontol A Biol Sci Med Sci*. 2014;69(7):779–89. <https://doi.org/10.1093/gerona/glt190>.
- Kronimus Y, Dodel R, Galuska SP, Neumann S. IgG Fc N-glycosylation: alterations in neurologic diseases and potential therapeutic target? *J Autoimmun*. 2019;96:14–23. <https://doi.org/10.1016/j.jaut.2018.10.006>.
- Lemmers RFH, Vilaj M, Urda D, Agakov F, Šimurina M, Klarić L, et al. IgG glycan patterns are associated with type 2 diabetes in independent European populations. *Biochim Biophys Acta Gen Subj*. 2017;1861(9):2240–9. <https://doi.org/10.1016/j.bbagen.2017.06.020>.
- Li X, Wang H, Russell A, Cao W, Wang X, Ge S, et al. Type 2 diabetes mellitus is associated with the immunoglobulin G N-glycome through putative proinflammatory mechanisms in an Australian Population. *OMICS*. 2019;23(12):631–9. <https://doi.org/10.1089/omi.2019.0075>.
- Liang B, Tang WW, Zhang WQ, Huang C, Liu Y, Xu F, et al. Prevalence and associated factors of diabetes mellitus in a very elderly Chinese population: a cross-sectional study. *Biomed Environ Sci*. 2020;33(5):315–22. <https://doi.org/10.3967/bes2020.043>.

- Ligthart S, Vaez A, Vösa U, Stathopoulou MG, de Vries PS, Prins BP, et al. Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders. *Am J Hum Genet.* 2018;103(5):691–706. <https://doi.org/10.1016/j.ajhg.2018.09.009>.
- Liu D, Chu X, Wang H, Dong J, Ge SQ, Zhao ZY, et al. The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia. *J Transl Med.* 2018a;16(1):235. <https://doi.org/10.1186/s12967-018-1616-2>.
- Liu D, Zhao Z, Wang A, Ge S, Wang H, Zhang X, et al. Ischemic stroke is associated with the pro-inflammatory potential of N-glycosylated immunoglobulin G. *J Neuroinflamm.* 2018b;15(1):123. <https://doi.org/10.1186/s12974-018-1161-1>.
- Liu D, Xu X, Li Y, Zhang J, Zhang X, Li Q, et al. Immunoglobulin G N-glycan analysis by ultra-performance liquid chromatography. *J vis Exp.* 2020. <https://doi.org/10.3791/60104>.
- Liu D, Tian QY, Zhang J, Hou HF, Li Y, Wang W, et al. Association between 25 hydroxyvitamin D concentrations and the risk of COVID-19: a Mendelian randomization study. *Biomed Environ Sci.* 2021;34(9):750–4. <https://doi.org/10.3967/bes2021.104>.
- Liu D, Dong J, Zhang J, Xu X, Tian Q, Meng X, et al. Genome-wide mapping of plasma IgG N-glycan quantitative trait loci identifies a potentially causal association between IgG N-glycans and rheumatoid arthritis. *J Immunol.* 2022;208(11):2508–14. <https://doi.org/10.4049/jimmunol.2100080>.
- Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nat Genet.* 2018;50(4):559–71. <https://doi.org/10.1038/s41588-018-0084-1>.
- Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. *J Biochem.* 2000;128(4):621–8. <https://doi.org/10.1093/oxfordjournals/jbchem.a022794>.
- Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and the altered glycan theory of autoimmunity: a critical review. *J Autoimmun.* 2015;57:1–13. <https://doi.org/10.1016/j.jaut.2014.12.002>.
- Nikolac Perkovic M, Pucic Bakovic M, Kristic J, Novokmet M, Huffman JE, Vitart V, et al. The association between galactosylation of immunoglobulin G and body mass index. *Prog Neuropsychopharmacol Biol Psychiatry.* 2014;48:20–5. <https://doi.org/10.1016/j.pnpbp.2013.08.014>.
- Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol.* 2008;8(1):34–47. <https://doi.org/10.1038/nri2206>.
- Novokmet M, Lukić E, Vučković F, Đurić Ž, Keser T, Rajšl K, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. *Sci Rep.* 2014;4:4347. <https://doi.org/10.1038/srep04347>.
- Pavić T, Dilber D, Kifer D, Selak N, Keser T, Ljubičić Đ, et al. N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease. *J Transl Med.* 2018;16(1):323. <https://doi.org/10.1186/s12967-018-1695-0>.
- Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest.* 2003;111(12):1805–12. <https://doi.org/10.1172/jci18921>.
- Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat JJ, et al. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. *Sci Rep.* 2017;7(1):12325. <https://doi.org/10.1038/s41598-017-12495-0>.
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA.* 2001;286(3):327–34. <https://doi.org/10.1001/jama.286.3.327>.
- Rudman N, Gornik O, Lauc G. Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. *FEBS Lett.* 2019;593(13):1598–615. <https://doi.org/10.1002/1873-3468.13495>.
- Russell AC, Šimurina M, Garcia MT, Novokmet M, Wang Y, Rudan I, et al. The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. *Glycobiology.* 2017;27(5):501–10. <https://doi.org/10.1093/glycob/cwx022>.
- Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. *Nat Genet.* 2018;50(7):912–9. <https://doi.org/10.1038/s41588-018-0152-6>.
- Singh SS, Heijmans R, Meulen CKE, Lieveve AG, Gornik O, Sijbrands EJG, et al. Association of the IgG N-glycome with the course of kidney function in type 2 diabetes. *BMJ Open Diabetes Res Care.* 2020. <https://doi.org/10.1136/bmjdc-2019-001026>.
- Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, et al. Identification of type 2 diabetes loci in 433,540 East Asian individuals. *Nature.* 2020;582(7811):240–5. <https://doi.org/10.1038/s41586-020-2263-3>.
- Štambuk J, Nakić N, Vučković F, Pučić-Baković M, Razdorov G, Trbojević-Akmačić I, et al. Global variability of the human IgG glycome. *Aging (Albany NY).* 2020;12(15):15222–59. <https://doi.org/10.18632/aging.103884>.
- Tanigaki K, Sacharidou A, Peng J, Chambliss KL, Yuhanna IS, Ghosh D, et al. Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance. *J Clin Invest.* 2018;128(1):309–22. <https://doi.org/10.1172/jci89333>.
- Testa R, Vanhooren V, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, et al. N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. *PLoS ONE.* 2015;10(3):e0119983. <https://doi.org/10.1371/journal.pone.0119983>.
- Trbojević Akmačić I, Ventham NT, Theodoratou E, Vučković F, Kennedy NA, Krištić J, et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. *Inflamm Bowel Dis.* 2015;21(6):1237–47. <https://doi.org/10.1097/mib.0000000000000372>.
- Tremblay J, Hamet P. Environmental and genetic contributions to diabetes. *Metabolism.* 2019;100s: 153952. <https://doi.org/10.1016/j.metabol.2019.153952>.
- Vučković F, Krištić J, Gudelj I, Teruel M, Keser T, Pezer M, et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. *Arthritis Rheumatol.* 2015;67(11):2978–89. <https://doi.org/10.1002/art.39273>.
- Wittenbecher C, Štambuk T, Kuxhaus O, Rudman N, Vučković F, Štambuk J, et al. Plasma N-glycans as emerging biomarkers of cardiometabolic risk: a prospective investigation in the EPIC-potsdam cohort study. *Diabetes Care.* 2020;43(3):661–8. <https://doi.org/10.2337/dc19-1507>.
- Yamaguchi Y, Barb AW. A synopsis of recent developments defining how N-glycosylation impacts immunoglobulin G structure and function. *Glycobiology.* 2020;30(4):214–25. <https://doi.org/10.1093/glycob/cwz068>.
- Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang LX. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIa receptor. *J Am Chem Soc.* 2011;133(46):18975–91. <https://doi.org/10.1021/ja208390n>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

